This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The 5 Dumbest Things on Wall Street This Week: Aug. 3

Stocks in this article: GMAAPLUBSKCGSTPDNDN

3. Dendreon's Demise

What a long strange trip it's been for our buddies at Dendreon (DNDN). And a round trip at that.

Shares of the volatile biotech outfit sank 22% to $4.80 Tuesday -- a level not seen since early 2009 -- after it announced that revenue for its prostate cancer drug Provenge tumbled in the second quarter. The company said Provenge sales fell more than 2% sequentially to $80 million, thereby raising a legitimate question about slowing demand for the company's franchise immunotherapy in the face of new competition.

And that's not the only question raised about Dendreon in the wake of its latest train wreck (Ah, who can forget last summer's destruction which sent the stock from $35 to $10? Talk about falling off a fiscal cliff!) TheStreet's biotech ax Adam Feuerstein came up with a fistful of problems facing the company.

"Dendreon insists that Johnson & Johnson's (JNJ) competitive drug Zytiga is not having an impact on Provenge but common sense argues otherwise . It seems pretty clear that Provenge has a demand problem and it's not going to get any better with Zytiga on a path towards approval in the pre-chemo setting and Medivation's (MDVN) MDV3100 moving fast behind it," says Feuerstein, who adds that the deep cost-cutting announced by Dendreon Monday is the right strategic move but won't be sufficient given Provenge's problems.

Furthermore, the eagle-eyed Feuerstein points out that oncologists flat-out detest Provenge.

"They're not prescribing the drug to their prostate cancer patients so why does Dendreon insist on wasting money and resources trying to convince them otherwise? The company would be more effective if they focused solely on marketing Provenge to urologists."

Speaking of urination, Feuerstein reports that there has been a steady stream of Dendreon sales reps leaving the company, possibly to rival J&J. So clearly Dendreon's investors are not the only ones getting the piss scared out of them.

And rightfully so.

3 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs